Compass Therapeutics: Canaccord Confirms Buy Recommendation with Price Target Increase to $13!
Reading Time: 2 minutes
Canaccord Upgrade and the Asymmetrical Risk Profile The price target increase for Compass Therapeutics (CMPX) by Canaccord Genuity to $13 (previously $10) on February 4, 2026, marks a crucial turning point in the valuation of Compass Therapeutics, as the focus now fully shifts to the upcoming release of pivotal Phase 2/3 data at the end of the first quarter of 2026. The analyst's commentary highlights an attractive asymmetrical risk-reward profile for biotech investors: an upside potential to $13 in the event of success is contrasted with a...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
